These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15911464)

  • 1. Effect of acyclovir on herpetic ocular recurrence using a structural nested model.
    Cole SR; Chu H
    Contemp Clin Trials; 2005 Jun; 26(3):300-10. PubMed ID: 15911464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sense and sensitivity when correcting for observed exposures in randomized clinical trials.
    Vansteelandt S; Goetghebeur E
    Stat Med; 2005 Jan; 24(2):191-210. PubMed ID: 15515152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part I: structural nested models and marginal structural models to test and estimate treatment arm effects.
    Yamaguchi T; Ohashi Y
    Stat Med; 2004 Jul; 23(13):1991-2003. PubMed ID: 15211598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation.
    Greenland S; Lanes S; Jara M
    Clin Trials; 2008; 5(1):5-13. PubMed ID: 18283074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of non-compliance on intent-to-treat analysis of equivalence trials.
    Sheng D; Kim MY
    Stat Med; 2006 Apr; 25(7):1183-99. PubMed ID: 16220491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of statistical methods for analysing survival data in the presence of non-random compliance.
    Odondi L; McNamee R
    Stat Med; 2010 Dec; 29(29):2994-3003. PubMed ID: 20963732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death.
    Cain LE; Cole SR
    Stat Med; 2009 May; 28(12):1725-38. PubMed ID: 19347843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preventive treatment with oral acyclovir of recurrent erythema multiforme, associated with herpes infection or not. Preliminary study].
    Morel P; Barth P
    Ann Dermatol Venereol; 1986; 113(3):269-70. PubMed ID: 3019211
    [No Abstract]   [Full Text] [Related]  

  • 9. Model misspecification sensitivity analysis in estimating causal effects of interventions with non-compliance.
    Jo B
    Stat Med; 2002 Nov; 21(21):3161-81. PubMed ID: 12375297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study.
    Miserocchi E; Modorati G; Galli L; Rama P
    Am J Ophthalmol; 2007 Oct; 144(4):547-51. PubMed ID: 17692271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study).
    Tanaka Y; Matsuyama Y; Ohashi Y;
    Stat Med; 2008 May; 27(10):1718-33. PubMed ID: 17922525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity analysis of intention-to-treat estimates when withdrawals are related to unobserved compliance status.
    Salim A; Mackinnon A; Griffiths K
    Stat Med; 2008 Apr; 27(8):1164-79. PubMed ID: 17724782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.
    Wang Y; Berlin JA; Pinheiro J; Wilcox MA
    Clin Trials; 2015 Jun; 12(3):265-75. PubMed ID: 25733675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline information in structural failure time estimators for the effect of observed treatment compliance.
    Loeys T; Goetghebeur E
    Stat Med; 2002 May; 21(9):1173-88. PubMed ID: 12111873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What's new: acyclovir for treatment of ocular viral infections.
    Wilhelmus KR; Jones DB
    Tex Med; 1983 Jul; 79(7):27-9. PubMed ID: 6312627
    [No Abstract]   [Full Text] [Related]  

  • 16. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial.
    Paz-Bailey G; Sternberg M; Puren AJ; Markowitz LE; Ballard R; Delany S; Hawkes S; Nwanyanwu O; Ryan C; Lewis DA
    J Infect Dis; 2009 Oct; 200(7):1039-49. PubMed ID: 19715417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Acyclovir treatment of herpes group virus infections in children with leukemia and other immunocompromised status].
    Sekine I; Utsmi J; Kuriya N; Auma O; Mimaya J; Shike S; Koizumi S; Imajuku S; Yamamoto S; Ninomiya T
    Rinsho Ketsueki; 1983 Sep; 24(9):1260-70. PubMed ID: 6319774
    [No Abstract]   [Full Text] [Related]  

  • 18. Acyclovir in the treatment of herpesvirus infections.
    Thiers BH
    Dermatol Clin; 1990 Jul; 8(3):583-7. PubMed ID: 2165881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acyclovir therapy in prevention of recurrent herpetic keratitis following penetrating keratoplasty.
    Ghosh S; Jhanji V; Lamoureux E; Taylor HR; Vajpayee RB
    Am J Ophthalmol; 2008 Feb; 145(2):198-202. PubMed ID: 18222189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weighting in instrumental variables and G-estimation.
    Joffe MM; Brensinger C
    Stat Med; 2003 Apr; 22(8):1285-303. PubMed ID: 12687655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.